Value of serum IL-10 level in evaluating the prognosis of bacillus calmette-guerin bladder perfusion therapy in the treatment of T1 non-muscular invasive bladder cancer
WANG Kaijian, HUANG Wei, LI Wei, SHEN Hongfeng
Department of Urology, the 928th Hospital of PLA Joint Logistics Support Force, Haikou 570216, China
AbstractObjective To investigate the value of serum IL-10 level in evaluating the prognosis of bacillus calmette-guerin (BCG) bladder perfusion therapy in the treatment of T1 non-muscular invasive bladder cancer (NMIBC). Methods A retrospective cohort study was conducted on 149 patients with high-risk T1 NMIBC who received BCG bladder perfusion therapy and transurethral electrotomy for bladder tumor (TURBT) from January 2017 to December 2021. General data of patients were collected and blood routine results of patients with TURBT 1 week before surgery were recorded. The results of cystoscopy were recorded and analyzed 3 months after operation. Serum samples were collected before and during BCG induction therapy, and serum IL-10 levels were detected by human IL-10 enzyme-linked immunosorbent assay kit, and comparative analysis was performed. Results Among 149 cases, 45 cases recurred within 6 months after induction therapy and were considered as non-responders to BCG, and the other 104 patients were considered responders. Serum IL-10 levels in non-responders were significantly higher than those in non-responders before BCG infusion into the bladder (baseline), in the early and middle stages of induction therapy and after treatment (P＜0.05). When baseline serum IL-10≥242.55 pg/ml, the area under the receiver operating characteristic curve (AUC) for predicting BCG treatment response was 0.729, the sensitivity was 66.70%, and the specificity was 74.0%. Changes in serum IL-10 levels from baseline to the last time point also distinguished well between BCG responders and non-responders (AUC=0.676). During a median follow-up of 42 months, 69 cases of tumor recurrence occurred. Patients were divided into high-risk group and low-risk group with median GSIL-10 value. The high risk group had a shorter recurrence-free survival (RFS) (P＜0.001) and a lower RFS rate (P=0.011) than the low risk group. COX proportional hazard regression analysis confirmed that high serum IL-10 level at baseline (HR=2.042, P=0.007) was an important variable for tumor recurrence in patients treated with BCG bladder perfusion. Conclusions Serum IL-10 may be a reliable marker for predicting the response and prognosis of NMIBC to BCG.
WANG Kaijian,HUANG Wei,LI Wei等. Value of serum IL-10 level in evaluating the prognosis of bacillus calmette-guerin bladder perfusion therapy in the treatment of T1 non-muscular invasive bladder cancer[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2024, 35(10): 860-866.
Bhindi B, Kool R, Kulkarni GS, et al. Canadian Urological Association guideline on the management of non muscle invasive bladder cancer Full text[J]. Can Urol Assoc J, 2021, 15(8): E424-E460.
[3]
Babjuk M, Burger M, Compérat E M, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (tat1 and carcinoma in situ) - 2019 update[J]. Eur Urol, 2019 , 76(5): 639-657.
[4]
Wang Z, So W Z, Loh K Y, et al. Predictive biomarkers of response to bacillus Calmette-Guérin immunotherapy and bacillus Calmette-Guérin failure for non-muscle invasive bladder cancer[J]. Int J Urol, 2022, 29(8): 807-815.
[5]
Queiroz N M, Marinho F V, Araujo A C, et al. MyD88-dependent BCG immunotherapy reduces tumor and regulates tumor microenvironment in bladder cancer murine model[J]. Sci Rep, 2021, 11(1): 15648.
Song D, Powles T, Shi L, et al. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches[J]. J Pathol, 2019, 249(2): 151-165.
[9]
Mukherjee N, Julián E, Torrelles J B, et al. Effects of Mycobacterium bovis Calmette et Guérin (BCG) in oncotherapy: Bladder cancer and beyond[J]. Vaccine, 2021, 39(50): 7332-7340.
Wigner P, Grębowski R, Bijak M, et al. The interplay between oxidative stress, inflammation and angiogenesis in bladder cancer development[J]. Int J Mol Sci, 2021, 22(9): 4483.
[12]
Jang D, Lee A H, Shin H Y, et al. The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics[J]. Int J Mol Sci, 2021, 22(5): 2719-2733.
Widodo S S, Dinevska M, Furst L M, et al. IL-10 in glioma[J]. Br J Cancer, 2021, 125(11): 1466-1476.
[18]
Cai T, Nesi G, Mazzoli S, et al. Prediction of response to bacillus Calmette-Guérin treatment in non-muscle invasive bladder cancer patients through interleukin-6 and interleukin-10 ratio[J]. Exp Ther Med, 2012, 4(3): 459-464.
2024, Vol. 35 
